Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
During the intervention and follow-up periods, there were no specific complications associated with REP or placebo supplementation.Within-group changes from baseline to the end of each intervention period and their between-group differences.NInterventionWithin-group changesBetween-group differences in within-group changesMean (%CI)Mean (%CI) P-valueDry weight (kg)49REP0.0 (−0.1 to 0.0)0.0 (−0.1 to 0.1)0.877Placebo−0.1 (−0.1 to 0.1)Skeletal muscle (kg)39REP−0.1 (−0.2 to 0.1)−0.2 (−0.6 to 0.1)0.182Placebo0.2 (−0.1 to 0.5)Fat mass (kg)39REP0.1 (−0.2 to 0.3)0.0 (−0.4 to 0.4)0.980Placebo0.1 (−0.2 to 0.4)Lean body mass (kg)39REP−0.1 (−0.4 to 0.2)−0.2 (−0.6 to 0.3)0.450Placebo0.1 (−0.3 to 0.3)MAC (cm)48REP0.3 (0.1 to 0.5)0.0 (−0.4 to 0.4)0.967Placebo0.3 (0.0 to 0.7)Skinfold thickness (cm)48REP0.5 (0.0 to 1.0)0.0 (−1.0 to 0.9)0.929Placebo0.5 (−0.2 to 1.3)Single-pool Kt/V49REP−0.01 (−0.04 to 0.02)0.0 (−0.1 to 0.0)0.199Placebo0.02 (−0.01 to 0.05)Total protein (g/dL)49REP−0.04 (−0.12 to 0.04)−0.04 (−0.17 to 0.09)0.518Placebo0.00 (−0.08 to 0.08)Albumin (g/dL)49REP−0.02 (−0.09 to 0.04)−0.08 (−0.17 to 0.01)0.075Placebo0.06 (0.01 to 0.11)Prealbumin (g/dL)49REP−0.8 (−1.7 to 0.1)−0.5 (−1.8 to 0.8)0.439Placebo−0.3 (−1.1 to 0.4)RBP (mg/dL)49REP−0.1 (−0.3 to 0.2)−0.1 (−0.5 to 0.3)0.474Placebo0.1 (−0.1 to 0.3)Transferrin (mg/dL)49REP−3.35 (−9.79 to 3.09)−2.9 (−11.8 to 6.1)0.531Placebo−1.59 (−8.02 to 4.83)Total cholesterol (mg/dL)49REP0 (−4 to 3)−4.1 (−9.1 to 0.9)0.103Placebo4 (1 to 7)Corrected calcium (mg/dL)49REP0.04 (−0.04 to 0.13)0.01 (−0.14 to 0.16)0.888Placebo0.03 (−0.05 to 0.12)25(OH)D (ng/mL)49REP−0.8 (−2.3 to 0.8)0.4 (−1.8 to 2.5)0.741Placebo−1.1 (−2.7 to 0.6)Ln(1,25D [pg/mL])49REP−0.04 (−0.12 to 0.04)0.00 (−0.10 to 0.11)0.953Placebo−0.04 (−0.11 to 0.03)Ln(intact PTH [pg/mL])49REP−0.07 (−0.17 to 0.03)−0.06 (−0.21 to 0.09)0.425Placebo−0.01 (−0.10 to 0.08)Ln(1 to 84 PTH [pg/mL])49REP0.08 (−0.19 to 0.03)−0.08 (−0.23 to 0.06)0.257Placebo0.00 (−0.09 to 0.10)Ln(FGF23 [pg/mL])49REP0.03 (−0.12 to 0.19)0.15 (−0.07 to 0.36)0.172Placebo−0.11 (−0.27 to 0.05)Hemoglobin (g/dL)49REP0.1 (−0.2 to 0.3)0.0 (−0.3 to 0.3)0.915Placebo0.0 (−0.1 to 0.2)Ln(glycated hemoglobin [%])49REP0.0 (0.0 to 0.0)0.0 (0.0 to 0.1)0.189Placebo0.0 (0.0 to 0.0)Ln(C-reactive protein [mg/dL])49REP0.00 (−0.29 to 0.29)0.04 (−0.32 to 0.40)0.814Placebo−0.04 (−0.27 to 0.18)1,25(OH)2D, 1,25-dihydroxyvitamin D; CI, confidence interval; FGF23, fibroblast growth factor-23; 25(OH)D, 25-hydroxyvitamin D; MAC, mid-upper arm circumference; PTH, parathyroid hormone; RBP, retinol-binding protein; REP, rice endosperm protein.
Source: Secondary Outcomes. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Double-blind reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
A Randomized, Double-Blind, Crossover Pilot Trial of Rice Endosperm Protein Supplementation in Maintenance Hemodialysis Patients
Source: Article title.
Adherence to REP and placebo in the study patients was both 99.5%.Figure 1Overall crossover design of this study.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
A Randomized, Double-Blind, Crossover Pilot Trial of Rice Endosperm Protein Supplementation in Maintenance Hemodialysis Patients
Study design awaiting verification · Scientific Reports · 2017
Original publication title
A Randomized, Double-Blind, Crossover Pilot Trial of Rice Endosperm Protein Supplementation in Maintenance Hemodialysis Patients
© The Author(s) 2017
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
In maintenance hemodialysis (MHD) patients, low protein intake is associated with protein-energy wasting, a risk factor that affects outcome. However, increased protein intake may lead to hyperphosphatemia and hyperkalemia, which are also mortality risk factors. Here, we evaluated the safety and effects of purified rice endosperm protein (REP), which contains less phosphorus and potassium than soy and casein proteins, as a supplemental protein source for MHD patients. This randomized, double-blind, placebo-controlled, crossover pilot study of REP supplementation (5 g/day × 4 weeks) was carried out in 50 Japanese adult MHD patients (1 dropped out); the primary outcome was the change in the urea kinetic-based normalized protein catabolic rate (nPCR), an indicator of protein intake in MHD patients.
Intention-to-treat analyses of 24 patients in the REP-first group and 25 in the placebo-first group showed that REP supplementation increased nPCR significantly by 0.07 g/kg/day (95% confidence interval, 0.03 to 0.11), whereas changes in serum phosphorus and potassium concentrations were not different from the placebo. REP supplementation did not show a significant effect on other nutritional or metabolic parameters and no specific complications. In conclusion, purified REP with efficient bioavailability may be safe and useful for dietary supplementation in MHD patients.
Authors’ abstract
In maintenance hemodialysis (MHD) patients, low protein intake is associated with protein-energy wasting, a risk factor that affects outcome. However, increased protein intake may lead to hyperphosphatemia and hyperkalemia, which are also mortality risk factors. Here, we evaluated the safety and effects of purified rice endosperm protein (REP), which contains less phosphorus and potassium than soy and casein proteins, as a supplemental protein source for MHD patients. This randomized, double-blind, placebo-controlled, crossover pilot study of REP supplementation (5 g/day × 4 weeks) was carried out in 50 Japanese adult MHD patients (1 dropped out); the primary outcome was the change in the urea kinetic-based normalized protein catabolic rate (nPCR), an indicator of protein intake in MHD patients.
Intention-to-treat analyses of 24 patients in the REP-first group and 25 in the placebo-first group showed that REP supplementation increased nPCR significantly by 0.07 g/kg/day (95% confidence interval, 0.03 to 0.11), whereas changes in serum phosphorus and potassium concentrations were not different from the placebo. REP supplementation did not show a significant effect on other nutritional or metabolic parameters and no specific complications. In conclusion, purified REP with efficient bioavailability may be safe and useful for dietary supplementation in MHD patients.
Publication and source details
Original title: A Randomized, Double-Blind, Crossover Pilot Trial of Rice Endosperm Protein Supplementation in Maintenance Hemodialysis Patients
Michihiro Hosojima; Hisaki Shimada; Yoshitsugu Obi; Shoji Kuwahara; Ryohei Kaseda; Hideyuki Kabasawa; Hazuki Kondo; Mikio Fujii; Reiko Watanabe; Yoshiki Suzuki; Motoni Kadowaki; Shigeru Miyazaki; Akihiko Saito
Scientific Reports · 2017
© The Author(s) 2017https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T19:21:27.858557+00:00
DOI: 10.1038/s41598-017-18340-8 · PMC5740176